<DOC>
	<DOCNO>NCT02148744</DOCNO>
	<brief_summary>This first-in-human ( FIH ) study randomize , double-blinded , placebo-controlled , ascend dose study investigate safety , tolerability , pharmacokinetics XmAb7195 adult healthy volunteer adult subject elevate IgE level .</brief_summary>
	<brief_title>Safety Tolerability XmAb®7195 Adult Healthy Volunteers Adult Subjects With History Allergic Rhinitis and/or Allergic Conjunctivitis and/or Atopic Dermatitis</brief_title>
	<detailed_description />
	<mesh_term>Rhinitis , Allergic</mesh_term>
	<mesh_term>Rhinitis</mesh_term>
	<mesh_term>Dermatitis</mesh_term>
	<mesh_term>Dermatitis , Atopic</mesh_term>
	<mesh_term>Eczema</mesh_term>
	<mesh_term>Conjunctivitis</mesh_term>
	<mesh_term>Conjunctivitis , Allergic</mesh_term>
	<criteria>Adult male females 18 50 year age Parts 1 3 : Healthy subject clinically significant abnormality identify medical laboratory evaluation history clinically significant disorder , condition , disease would pose risk subject safety interfere study evaluation , procedure , completion ; Part 2 : Otherwise healthy male female subject history allergic rhinitis and/or allergic conjunctivitis and/or atopic dermatitis elevate serum IgE Subjects able willing give write informed consent ; Subjects ability complete study assessment ; Subjects willing forego form experimental treatment study . Subjects clinically relevant history presence respiratory , gastrointestinal , renal , hepatic , hematological , lymphatic , neurological , cardiovascular , psychiatric , musculoskeletal , genitourinary , immunological , dermatological , connective tissue disease , disorder ( allergic rhinitis and/or conjunctivitis and/or atopic dermatitis Part 2 ) would pose significant risk subject safety significantly interfere study evaluation , procedure , completion Subjects positive hepatitis B surface antigen ( HBsAg ) , hepatitis C virus ( HCV ) antibody and/or human immunodeficiency virus ( HIV ) Type I Type II test Screening ; Subjects agree use medically acceptable method contraception ( define protocol ) ; Subject pregnant breast feeding , plan become pregnant within 3 month administration XmAb7195 ; Subjects use investigational drug clinical trial within 8 week prior admission ( Day 1 ) , use experimental monoclonal antibody ; Subjects prior exposure monoclonal antibody ; Subjects history anaphylaxis ; Subjects receive live vaccine ≤ 3 month Screening ;</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>